留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

Hydrophilic/hydrophobic characters of antimicrobial peptides derived from animals and their effects on multidrug resistant clinical isolates

Cun-Bao LIU Bin SHAN Hong-Mei BAI Jing TANG Long-Zong YAN Yan-Bing MA

Cun-Bao LIU, Bin SHAN, Hong-Mei BAI, Jing TANG, Long-Zong YAN, Yan-Bing MA. Hydrophilic/hydrophobic characters of antimicrobial peptides derived from animals and their effects on multidrug resistant clinical isolates. Zoological Research, 2015, 36(1): 41-47. doi: 10.13918/j.issn.2095-8137.2015.1.41
Citation: Cun-Bao LIU, Bin SHAN, Hong-Mei BAI, Jing TANG, Long-Zong YAN, Yan-Bing MA. Hydrophilic/hydrophobic characters of antimicrobial peptides derived from animals and their effects on multidrug resistant clinical isolates. Zoological Research, 2015, 36(1): 41-47. doi: 10.13918/j.issn.2095-8137.2015.1.41

Hydrophilic/hydrophobic characters of antimicrobial peptides derived from animals and their effects on multidrug resistant clinical isolates

doi: 10.13918/j.issn.2095-8137.2015.1.41
基金项目: This study was supported by the Peking Union Medical College (PUMC) Youth Fund and the Fundamental Research Funds for the Central Universities, China (333203084)
详细信息
    通讯作者:

    Yan-Bing MA

Hydrophilic/hydrophobic characters of antimicrobial peptides derived from animals and their effects on multidrug resistant clinical isolates

Funds: This study was supported by the Peking Union Medical College (PUMC) Youth Fund and the Fundamental Research Funds for the Central Universities, China (333203084)
More Information
    Corresponding author: Yan-Bing MA
  • 摘要: Multidrug resistant (MDR) pathogen infections are serious threats to hospitalized patients because of the limited therapeutic options. A novel group of antibiotic candidates, antimicrobial peptides (AMPs), have recently shown powerful activities against both Gram-negative and Gram-positive bacteria. Unfortunately, the viability of using these AMPs in clinical settings remains to be seen, since most still need to be evaluated prior to clinical trials and not all of AMPs are potent against MDR clinical isolates. To find a connection between the characteristics of several of these AMPs and their effects against MDR pathogens, we selected 14 AMPs of animal origin with typical structures and evaluated their in vitro activities against clinical strains of extensive drug-resistant Acinetobacter baumannii, methicillin-resistant Staphylococcus aureus, extended spectrum β-lactamase-producing Pseudomonas aeruginosa and extended spectrum β-lactamase-producing Escherichia coli. Our results showed that these peptides' hydrophilic/hydrophobic characteristics, rather than their secondary structures, may explain their antibacterial effects on these clinical isolates. Peptides that are amphipathic along the longitudinal direction seemed to be effective against Gram-negative pathogens, while peptides with hydrophilic terminals separated by a hydrophobic intermediate section appeared to be effective against both Gram-negative and Gram-positive pathogens. Among these, cathelicidin-BF was found to inhibit all of the Gram-negative pathogens tested at dosages of no more than 16 mg/L, killing a pandrug-resistant A. baumannii strain within 2 h at 4×MICs and 4 h at 2×MICs. Tachyplesin III was also found capable of inhibiting all Gram-negative and Gram-positive pathogens tested at no more than 16 mg/L, and similarly killed the same A. baumannii strain within 4 h at 4×MICs and 2×MICs. These results suggest that both cathelicidin-BF and tachyplesin III are likely viable targets for the development of AMPs for clinical uses.
  • [1] Brogden KA. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nature Reviews Microbiology, 3(3): 238-250.
    [2] Chromek M, Slamová Z, Bergman P, Kovács L, Podracká L, Ehrén I, Hökfelt T, Gudmundsson GH, Gallo RL, Agerberth B, Brauner A. 2006. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nature Medicine, 12(6): 636-641.
    [3] Cirioni O, Ghiselli R, Silvestri C, Kamysz W, Orlando F, Mocchegiani F, Di Matteo F, Riva A, ?ukasiak J, Scalise G, Saba V, Giacometti A. 2007. Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain. Antimicrobial Agents and Chemotherapy, 51(6): 2005-2010.
    [4] Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. M100-S23. Wayne, PA.
    [5] Conlon JM, Ahmed E, Condamine E. 2009. Antimicrobial properties of brevinin-2-related peptide and its analogs: Efficacy against multidrug-resistant Acinetobacter baumannii. Chemical Biology & Drug Design, 74(5): 488-493.
    [6] Conlon JM, Ahmed E, Pal T, Sonnevend A. 2010. Potent and rapid bactericidal action of alyteserin-1c and its [E4K] analog against multidrug-resistant strains of Acinetobacter baumannii. Peptides, 31(10): 1806-1810.
    [7] Falagas ME, Karageorgopoulos DE. 2008. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clinical Infectious Diseases, 46(7): 1121-1122.
    [8] Giacometti A, Cirioni O, Kamysz W, D'Amato G, Silvestri C, Del Prete MS, ?ukasiak J, Scalise G. 2003. Comparative activities of cecropin A, melittin, and cecropin A-melittin peptide CA(1-7)M(2-9)NH2 against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. Peptides, 24(9): 1315-1318.
    [9] Giacometti A, Cirioni O, Kamysz W, D'Amato G, Silvestri C, Del Prete MS, Licci A, Riva A, ?ukasiak J, Scalise G. 2005. In vitro activity of the histatin derivative P-113 against multidrug-resistant pathogens responsible for pneumonia in immunocompromised patients. Antimicrobial Agents and Chemotherapy, 49(3): 1249-1252.
    [10] Halverson T, Basir YJ, Knoop FC, Conlon JM. 2000. Purification and characterization of antimicrobial peptides from the skin of the North American green frog Rana clamitans. Peptides, 21(4): 469-476.
    [11] Hancock RE, Sahl HG. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nature Biotechnology, 24(12): 1551-1557.
    [12] Isenberg HD. 2004. Clinical Microbiology Procedures Handbook. Washington DC: ASM Press.
    [13] Knappe D, Piantavigna S, Hansen A, Mechler A, Binas A, Nolte O, Martin LL, Hoffmann R. 2010. Oncocin (VDKPPYLPRPRPPRRI YNR-NH2): a novel antibacterial peptide optimized against gram-negative human pathogens. Journal of Medicinal Chemistry, 53(14): 5240-5247.
    [14] Lipsky BA, Holroyd KJ, Zasloff M. 2008. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clinical Infectious Diseases, 47(12): 1537-1545.
    [15] Ouellette AJ, Miller SI, Henschen AH, Selsted ME. 1992. Purification and primary structure of murine cryptdin-1, a Paneth cell defensin. FEBS Letters, 304(2-3): 146-148.
    [16] Pagès JM, Dimarcq JL, Quenin S, Hetru C. 2003. Thanatin activity on multidrug resistant clinical isolates of Enterobacter aerogenes and Klebsiella pneumoniae. International Journal of Antimicrobial Agents, 22(3): 265-269.
    [17] Routsias JG, Karagounis P, Parvulesku G, Legakis NJ, Tsakris A. 2010. In vitro bactericidal activity of human β-defensin 2 against nosocomial strains. Peptides, 31(9): 1654-1660.
    [18] Selsted ME, Novotny MJ, Morris WL, Tang YQ, Smith W, Cullor JS. 1992. Indolicidin, a novel bactericidal tridecapeptide amide from neutrophils. The Journal of Biological Chemistry, 267(7): 4292-4295.
    [19] The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee. 2006. EUCAST technical note on tigecycline. Clinical Microbiology and Infection, 12(11): 1147-1149.
    [20] Thévenet P, Shen YM, Maupetit J, Guyon F, Derreumaux P, Tufféry P. 2012. PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides. Nucleic Acids Research, 40(W1): W288-293.
    [21] Thomas-Virnig CL, Centanni JM, Johnston CE, He LK, Schlosser SJ, Van Winkle KF, Chen RB, Gibson AL, Szilagyi A, Li LJ, Shankar R, Allen-Hoffmann BL. 2009. Inhibition of multidrug-resistant Acinetobacter baumannii by nonviral expression of hCAP-18 in a bioengineered human skin tissue. Molecular Therapy, 17(3): 562-569.
    [22] Vaara M. 2009. New approaches in peptide antibiotics. Current Opinion in Pharmacology, 9(5): 571-576.
    [23] Wang G, Li X, Wang Z. 2009. APD2: the updated antimicrobial peptide database and its application in peptide design. Nucleic Acids Research, 37(Database issue): D933-D937.
    [24] Wang YP, Hong J, Liu XH, Yang HL, Liu R, Wu J, Wang AL, Lin DH, Lai R. 2008. Snake cathelicidin from Bungarus fasciatus is a potent peptide antibiotics. PLos One, 3(9): e3127.
  • 加载中
计量
  • 文章访问数:  804
  • HTML全文浏览量:  110
  • PDF下载量:  1449
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-07-28
  • 修回日期:  2014-11-06
  • 刊出日期:  2015-01-08

目录

    /

    返回文章
    返回